These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 6285121)
21. Manipulation of the immune response by Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus: consequences for tumor development. Ressing ME; Wiertz EJ Semin Cancer Biol; 2008 Dec; 18(6):379-80. PubMed ID: 18992819 [No Abstract] [Full Text] [Related]
22. Assessment and characterization of the cytolytic T lymphocyte response against Epstein-Barr virus in patients with non-Hodgkin's lymphoma after autologous peripheral blood stem cell transplantation. Nolte A; Buhmann R; Straka C; Emmerich B; Hallek M Bone Marrow Transplant; 1998 May; 21(9):909-16. PubMed ID: 9613783 [TBL] [Abstract][Full Text] [Related]
23. Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Hamilton-Dutoit SJ; Rea D; Raphael M; Sandvej K; Delecluse HJ; Gisselbrecht C; Marelle L; van Krieken HJ; Pallesen G Am J Pathol; 1993 Oct; 143(4):1072-85. PubMed ID: 8214003 [TBL] [Abstract][Full Text] [Related]
24. Dominant Epstein-Barr virus-specific T-cell responses are maintained during moderate and intense immunosuppressive treatment. Daikeler T; Hoenger G; Oehri I; Tyndall A; Gratwohl A; Brander C; Klimkait T; Gasser O; Hess C Ann Rheum Dis; 2011 Feb; 70(2):395-6. PubMed ID: 20643766 [No Abstract] [Full Text] [Related]
26. Increased anti-Epstein-Barr virus antibodies in epidermotropic cutaneous T-cell lymphoma: a study of 64 patients. Jumbou O; Mollat C; N'Guyen JM; Billaudel S; Litoux P; Dréno B Br J Dermatol; 1997 Feb; 136(2):212-6. PubMed ID: 9068734 [TBL] [Abstract][Full Text] [Related]
27. Detection of Epstein-Barr virus in transformations of low-grade B-cell lymphomas after fludarabine treatment. Shields DJ; Byrd JC; Abbondanzo SL; Lichy JH; Diehl LF; Aguilera NI Mod Pathol; 1997 Nov; 10(11):1151-9. PubMed ID: 9388067 [TBL] [Abstract][Full Text] [Related]
28. Epstein-Barr virus in non-Hodgkin's lymphomas of the upper respiratory tract: association with sinonasal localization and expression of NK and/or T-cell antigens by tumour cells. Kanavaros P; Briere J; Lescs MC; Gaulard P J Pathol; 1996 Mar; 178(3):297-302. PubMed ID: 8778335 [TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus in Hodgkin's disease. Herbst H Semin Cancer Biol; 1996 Aug; 7(4):183-9. PubMed ID: 8946602 [TBL] [Abstract][Full Text] [Related]
30. The MLC response of patients with infectious mononucleosis to Epstein-Barr virus-transformed cells. Wasik M; Myc A; Matej H; Rudzka L Arch Immunol Ther Exp (Warsz); 1983; 31(6):871-8. PubMed ID: 6331340 [TBL] [Abstract][Full Text] [Related]
31. Human herpesvirus 6 and Epstein-Barr virus in Hodgkin's disease: a controlled study by polymerase chain reaction and in situ hybridization. Valente G; Secchiero P; Lusso P; Abete MC; Jemma C; Reato G; Kerim S; Gallo RC; Palestro G Am J Pathol; 1996 Nov; 149(5):1501-10. PubMed ID: 8909240 [TBL] [Abstract][Full Text] [Related]
32. What are the links between Epstein-Barr virus, lymphoma, and tumor necrosis factor antagonism in rheumatoid arthritis? Balandraud N; Roudier J; Roudier C Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):31-3. PubMed ID: 15852253 [TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus in B-cell non-Hodgkin's lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. Hummel M; Anagnostopoulos I; Korbjuhn P; Stein H J Pathol; 1995 Mar; 175(3):263-71. PubMed ID: 7745495 [TBL] [Abstract][Full Text] [Related]
34. CD8(+) T lymphocytes reactive against Epstein-Barr virus antigens in skin lesions of a patient with Sézary syndrome. Knol AC; Guilloux Y; Quéreux G; Marques-Briand S; Pandolfino MC; Khammari A; Dreno B J Am Acad Dermatol; 2005 Nov; 53(5):897-900. PubMed ID: 16243153 [TBL] [Abstract][Full Text] [Related]
35. Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. Wheatley GH; McKinnon KP; Iacobucci M; Mahon S; Gelber C; Lyerly HK Surgery; 1998 Aug; 124(2):171-6. PubMed ID: 9706135 [TBL] [Abstract][Full Text] [Related]
36. [Killer T cell activity specific to Epstein-Barr virus in patients with uterine cervical cancer]. Kitano Y; Fujisaki S; Okamura H Nihon Sanka Fujinka Gakkai Zasshi; 1988 May; 40(5):647-8. PubMed ID: 2838557 [No Abstract] [Full Text] [Related]
37. Leukocyte migration inhibition demonstrates a human T-cell response to a membrane protein expressed in latent Epstein-Barr virus infection. Sulitzeanu D; Szigeti R; Klein G; Hennessy K; Kieff E J Virol; 1986 Apr; 58(1):230-2. PubMed ID: 3005653 [TBL] [Abstract][Full Text] [Related]
38. [Tonsils and viral diseases]. Sesterhenn K Dtsch Z Mund Kiefer Gesichtschir; 1984; 8(2):93-9. PubMed ID: 6098399 [No Abstract] [Full Text] [Related]
39. [Leukocyte migration inhibition evoked by Epstein Barr virus antigen. I. Immune response in healthy donors]. Szigeti R; Klein G; Luka J; Volsky DJ Orv Hetil; 1981 Sep; 122(38):2327-31. PubMed ID: 6273776 [No Abstract] [Full Text] [Related]
40. EGNA-specific LIF production of human lymphocyte subsets. Szigeti R; Masucci G; Ehlin-Henriksson B; Bendtzen K; Henle G; Henle W; Klein G; Klein E Cell Immunol; 1984 Jan; 83(1):136-41. PubMed ID: 6319032 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]